Terence Flynn
Stock Analyst at Morgan Stanley
(3.96)
# 543
Out of 4,900 analysts
200
Total ratings
58.1%
Success rate
8.19%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $12.30 | +30.13% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $35.86 | +50.59% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $82.13 | +19.32% | 17 | Jul 10, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $169 → $171 | $164.37 | +4.03% | 22 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $47.02 | -27.69% | 11 | Jul 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $132 → $133 | $111.27 | +19.53% | 4 | Jul 10, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,133 → $1,135 | $790.51 | +43.58% | 20 | Jul 10, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $348 → $328 | $298.62 | +9.84% | 10 | Jul 10, 2025 | |
| ARVN Arvinas | Maintains: Equal-Weight | $12 → $11 | $7.42 | +48.25% | 9 | May 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $24 → $22 | $9.24 | +138.10% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $9.61 | +4.06% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $241 → $250 | $190.21 | +31.43% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $330 | $295.65 | +11.62% | 8 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $63 | $13.22 | +376.55% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $54.20 | -40.96% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $11.92 | -7.72% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $31 | $24.76 | +25.20% | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $19.32 | +510.77% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $3.47 | +937.46% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $129.36 | +29.88% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.05 | +290.24% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $128.06 | +240.47% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $317.67 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.57 | - | 1 | Jul 21, 2017 |
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $12.30
Upside: +30.13%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $35.86
Upside: +50.59%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $82.13
Upside: +19.32%
Johnson & Johnson
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $169 → $171
Current: $164.37
Upside: +4.03%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $47.02
Upside: -27.69%
BioNTech SE
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $111.27
Upside: +19.53%
Eli Lilly and Company
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $790.51
Upside: +43.58%
United Therapeutics
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $298.62
Upside: +9.84%
Arvinas
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $7.42
Upside: +48.25%
Arcus Biosciences
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $9.24
Upside: +138.10%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.61
Upside: +4.06%
Apr 28, 2025
Maintains: Overweight
Price Target: $241 → $250
Current: $190.21
Upside: +31.43%
Apr 9, 2025
Maintains: Equal-Weight
Price Target: $328 → $330
Current: $295.65
Upside: +11.62%
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $13.22
Upside: +376.55%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $54.20
Upside: -40.96%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $11.92
Upside: -7.72%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $30 → $31
Current: $24.76
Upside: +25.20%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $19.32
Upside: +510.77%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $3.47
Upside: +937.46%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $129.36
Upside: +29.88%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.05
Upside: +290.24%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $128.06
Upside: +240.47%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $317.67
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $7.57
Upside: -